Antibody Drug Delivery Systems Marketing Protein 
Roots Analysis
FEBRUARY 26, 2024
In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion.
Roots Analysis
MARCH 21, 2022
Subcutaneous biologics – current market landscape. Subcutaneous drug delivery systems – the helping hand for patients. There has been a significant increase in the number of biologics, specifically the new generation molecules, such as monoclonal antibodies, in the late-stage clinical studies ( phase II / phase III ).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MARCH 13, 2022
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Future Evolution of Biopharmaceutical Excipient Manufacturing Market. Our Social Media Platform. Web: [link]. LinkedIn: [link].
Roots Analysis
SEPTEMBER 13, 2023
Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.
XTalks
AUGUST 30, 2022
CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. Vornov, nusinersen is driving much of what is being currently seen in drug development.
Expert insights. Personalized for you.
52 
Let's personalize your content